Company Reports

Recent Updates

All Reports

Stock Analyst Note

Sanofi reported third-quarter net sales growth of 14% and business EPS growth of 20% at constant currencies. Management upgraded full-year guidance to low-teens sales growth, up from around 10%, and mid-teens business EPS growth. Ordinary shares closed up 5% from the previous day's close.
Stock Analyst Note

Sanofi reported second-quarter net sales growth of 18% and business EPS growth of 33% at constant currencies, fueled by Dupixent's outstanding performance. Management updated full-year guidance to around 10% sales growth and slightly faster business EPS growth. Sanofi's Paris-listed shares fell 9%.
Stock Analyst Note

Sanofi reported net sales growth of 14% and business EPS growth of 14% at constant currencies. Management affirmed its guidance for high-single-digit sales growth and slightly faster business EPS growth. Shares are about 1% higher than the previous day's close.
Stock Analyst Note

Sanofi reported net sales growth of 7% at constant currency and business earnings per share growth of 13%. Despite lower flu vaccine sales, Dupixent and Altuviiio continued to drive growth, and management reiterated its full-year guidance of low-double-digit business EPS growth.
Stock Analyst Note

Sanofi has entered into an agreement to acquire Blueprint Medicines for $129 per share, or about $9.1 billion. Additional contingent value rights bring the total potential deal value to $9.5 billion. Blueprint is a commercial-stage biotech company focused on mast-cell-driven diseases.
Stock Analyst Note

President Trump released an executive order on May 12 calling for a 30-day negotiation period between the Department of Health and Human Services and the biopharma industry, with the threat of a rule from the Centers for Medicare and Medicaid Services to lower US drug prices if no deal is reached.
Stock Analyst Note

Wide-moat Sanofi’s fourth-quarter results and 2025 guidance were in line with expectations. The company also announced a share buyback program of EUR 5 billion and proposed to increase its dividend to EUR 3.92 per share, a more than 4% increase, which we view as incrementally positive. The outlook for 2025 looks attractive given lack of major loss of exclusivity events, foreign exchange tailwinds, and the potential for significant pipeline news flow. We maintain our fair values of EUR 117 per ordinary share and $63 per US ADR.

Sponsor Center